Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
- 31 May 2009
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (8), 1397-1406
- https://doi.org/10.1016/j.ejca.2008.12.016
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.Journal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Mechanisms of Disease: angiogenesis and the management of breast cancerNature Clinical Practice Oncology, 2007
- Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantationBone Marrow Transplantation, 2007
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeNew England Journal of Medicine, 2007
- Cost of Cancer Care: Issues and ImplicationsJournal of Clinical Oncology, 2007
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter?Value in Health, 2004
- What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?Archives of Internal Medicine, 2003
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000